Endocyte Inc
(NASDAQ: ECYT)
+0.07
+0.49%
| Exchange: | NASDAQ |
| Stock: | Endocyte, Inc. |
| Industry: | Drug Manufacturers - Major |
| Employees: | 71 |
| Endocyte, Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its technology to create small molecule drug conjugates (SMDCs), and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, primarily to healthy cells. The Company’s SMDCs consists of three modules: a targeting ligand, a linker and a drug payload. The foundation of its technology is its small molecule targeting ligands, which bind to over-expressed receptors on target cells, while avoiding healthy cells. It is developing a number of different targeting ligands for a range of cancers and inflammatory diseases. Its linker system attaches the targeting ligand to the drug payload. The drug payload is the biologically active component of its SMDCs. Endocyte’s core SMDC, EC145, targets the folate receptor. |
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
